| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: =99.93%
| Targets |
Acetylcholinesterase (AChE); P-glycoprotein (P-gp)
|
|---|---|
| ln Vitro |
In cardiomyocytes, sinapine (6 or 60 μM; 1 hour) counteracts the oxidative stress caused by H2O2 and antimycin A on the mitochondria [1]. With relatively low toxicity, sinapine (10-200 μM; 24 h) suppresses Caco-2 cell proliferation in a dose-dependent manner [3]. By causing a reduction in P-glycoprotein (P-gp), sinapine (10-200 μM; 24 hours) stimulates the accumulation of doxorubicin in Caco-2 cells [3]. The phosphorylation of ERK1/2 and FRS2α is considerably reduced by sinapine (10-200 μM; 24 hours) [3].
|
| ln Vivo |
By altering the makeup of the intestinal microbiota in mice, sinapine lowers the incidence of non-alcoholic fatty liver disease [2].
|
| Cell Assay |
The Caco-2 cells are seeded into a 96-well plate with 8000 cells/well for 24 h. After incubation with different doses of Sinapine (0-200 μM), doxorubicin, or both for 24 h, the medium is discarded. Cell survival after exposure to Sinapine alone or a combination of Sinapine and the anti-tumor agent doxorubicin is examined by MTT colorimetric assay[3].
|
| Animal Protocol |
Rats: Sixty male Sprague-Dawley rats (95 g) are randomly allotted to 6 groups of 10 rats each and reared in individual cages. Six groups of 10 growing rats each are fed ad libitum for 15 days one of six diets: diet A, rapeseed (3.80 g of sinapine/kg DM); diet B, ethanol/water-extracted rapeseed (0.48 g of sinapine); diet C, control diet; diet G, control diet+3.74 g of extracted sinapine; diet H, control diet + 3.72 g of sinapine+other phenolic compounds; or diet I, control diet+the hydrolysis products of sinapine and other phenolic compounds. The rats are weighed at 8 a.m. on days 1, 4, 8, 11 and 15 of the trial. After sacrifice the gut contents are eliminated to permit determination of empty body weight gain (EBWG). The distribution, refusal and intake of each rat are recorded every day[4].
|
| References |
[1]. Boulghobra D, et, al. Sinapine, but not sinapic acid, counteracts mitochondrial oxidative stress in cardiomyocytes. Redox Biol. 2020 Jul;34:101554.
[2]. Li Y, et, al. Sinapine reduces non-alcoholic fatty liver disease in mice by modulating the composition of the gut microbiota. Food Funct. 2019 Jun 19;10(6):3637-3649. [3]. Guo Y, et al. Sinapine as an active compound for inhibiting the proliferation of Caco-2 cells via downregulation of P-glycoprotein. Food Chem Toxicol. 2014 May;67:187-92. [4]. Yates K, et, al. Determination of sinapine in rapeseed pomace extract: Its antioxidant and acetylcholinesterase inhibition properties. Food Chem. 2019 Mar 15;276:768-775. [4]. Valorization of rapeseed meal. 5. Effects of sinapine and other phenolic compounds on food intake and nutrient utilization in growing rats. Reprod Nutr Dev. 1987;27(4):781-90. |
| Additional Infomation |
Sinapine is an acylcholine in which the acyl group specified is sinapoyl. It has a role as a photosynthetic electron-transport chain inhibitor, an antioxidant and a plant metabolite. It is functionally related to a trans-sinapic acid.
|
| Molecular Formula |
C16H24NO5
|
|---|---|
| Molecular Weight |
310.3655
|
| Exact Mass |
310.16
|
| Elemental Analysis |
C, 61.92; H, 7.79; N, 4.51; O, 25.77
|
| CAS # |
18696-26-9
|
| Related CAS # |
Sinapine thiocyanate;7431-77-8;Sinapine hydroxide;122-30-5
|
| PubChem CID |
5280385
|
| Appearance |
Off-white to yellow solid
|
| Melting Point |
171.0-173.5ºC (dec.)
|
| Source |
Seeds of the cruciferous species
|
| LogP |
1.672
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
22
|
| Complexity |
363
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C(/C(/[H])=C(\[H])/C1C([H])=C(C(=C(C=1[H])OC([H])([H])[H])O[H])OC([H])([H])[H])=O)C([H])([H])C([H])([H])[N+](C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H]
|
| InChi Key |
HUJXHFRXWWGYQH-UHFFFAOYSA-O
|
| InChi Code |
InChI=1S/C16H23NO5/c1-17(2,3)8-9-22-15(18)7-6-12-10-13(20-4)16(19)14(11-12)21-5/h6-7,10-11H,8-9H2,1-5H3/p+1
|
| Chemical Name |
Ethanaminium, 2-((3-(4-hydroxy-3,5-dimethoxyphenyl)-1-oxo-2-propenyl)oxy)-N,N,N-trimethyl-
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~322.21 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.70 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.70 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2220 mL | 16.1098 mL | 32.2196 mL | |
| 5 mM | 0.6444 mL | 3.2220 mL | 6.4439 mL | |
| 10 mM | 0.3222 mL | 1.6110 mL | 3.2220 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA